Shots: The P-II TORTUGA study is assessing safety and efficacy in moderate to severe ankylosing spondylitis (AS) adults in ratio of 1:1 administering filgotinib 200 mg or PBO qw for 12 wks. TORTUGA results (N=116): improvement in AS disease, ASAS20 response (76% vs 40%), ASDAS (-1.5 vs -0.6) with no new safety signals and deaths […]Read More
Tags : Filgotinib (JAK1i)
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US